Reports
Sale
Global Phosphoinositide 3-Kinase Inhibitors Market Size: By Application: CLL - Chronic lymphocytic leukaemia, FL - Follicular lymphoma; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis, Key Indicators for Demand, Key Indicators for Price; Competitive Landscape; 2024-2032
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook
The global phosphoinositide 3-kinase (PI3K) inhibitors market is projected to grow at a CAGR of 4.65% over the forecast period of 2024-2032.
-inhibitors-market.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Targeted therapy for small molecules uses PI3K inhibitors that are relatively new in the area of oncology treatment. The development in the field of targeted therapy and their approvals are driving the growth of the industry globally. The governments across the nations have taken various measures to cut down the cost of these drugs to help patients. Such programmes help patients receive treatment at an affordable price. Thus, the emergence of such reimbursement schemes is one of the key market developments that will fuel the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.
Market Segmentation
A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a therapeutic drug class that works by inhibiting one or more of the 3-kinase phosphoinositide enzymes.
-inhibitors-market-by-application.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global phosphoinositide 3-kinase (PI3K) inhibitors industry can be broadly categorised based on its applications and regions.
- Application
- CLL - Chronic Lymphocytic Leukaemia
- FL - Follicular Lymphoma
- Others
The EMR report looks into the regional phosphoinositide 3-kinase (PI3K) inhibitors markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
-inhibitors-market-by-region.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The rising prevalence of cancer around the globe has resulted in the increased demand for chemotherapy and other treatment procedures. Chemotherapy drugs play a significant role in treating cancer. Their drawbacks, however, have produced a change from conventional chemotherapy to targeted therapies. As a result, extensive ongoing research is being performed on targeted therapies such as PI3K inhibitors with demonstrated effectiveness in oncology applications. Significant R&D has contributed to tailored treatments in the dominant therapeutic category. Thus, the recent launches and approvals of targeted therapy during the forecast period will contribute to the growth of phosphoinositide 3-kinase (PI3K) inhibitors industry globally. Although the complex manufacturing process of such drugs makes them expensive, which is becoming a significant challenge for manufacturers and may hamper the industry growth over the forecast period.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global phosphoinositide 3-kinase (PI3K) inhibitors market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Bayer AG
- Gilead Sciences Inc.
- Novartis AG
- TG Therapeutics Inc.
- Verastem Inc.
- Others
The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
8.1 Key Industry Highlights
8.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market (2018-2023)
8.3 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast (2024-2032)
8.4 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Application
8.4.1 CLL - Chronic lymphocytic leukaemia
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 FL - Follicular lymphoma
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.5 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Region
8.5.1 North America
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Europe
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Asia Pacific
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Latin America
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Middle East and Africa
8.5.5.1 Historical Trend (2018-2023)
8.5.5.2 Forecast Trend (2024-2032)
9 North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Bayer AG
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Gilead Sciences, Inc.
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Novartis AG
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 TG Therapeutics, Inc.
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Verastem, Inc.
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Key Industry Highlights, 2018 and 2032
2. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Application (USD Million), 2018-2023
3. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Application (USD Million), 2024-2032
4. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Region (USD Million), 2018-2023
5. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Region (USD Million), 2024-2032
6. North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
7. North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
8. Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
9. Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
10. Asia Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
11. Asia Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Latin America Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
13. Latin America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Middle East and Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
15. Middle East and Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Structure
Key Questions Answered in the Report
The global phosphoinositide 3-kinase (PI3K) inhibitors market is projected to grow at a CAGR of 4.65% between 2021 and 2026.
The major drivers of the industry, such as the rising prevalence of cancer, growing demand for targeted therapies, favourable government initiatives, and growing technological advancements, are expected to aid the market growth.
The key market trends guiding the growth of the phosphoinositide 3-kinase (PI3K) inhibitors industry include the ongoing research activities and fresh approval of targeted therapies.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
CLL (chronic lymphocytic leukaemia) and FL (follicular lymphoma) are the leading applications of phosphoinositide 3-kinase (PI3K) inhibitors in the industry.
The major players in the industry are Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc., among others.
Analyst Review
The global phosphoinositide 3-kinase (PI3K) inhibitors market is being driven by the growing cases of cancer, reimbursement schemes, and the growing demand for chemotherapy. Aided by the growing research and development activities, the market is expected to witness a healthy growth in the forecast period of 2024-2032, growing at a CAGR of 4.65%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on applications, the phosphoinositide 3-kinase (PI3K) inhibitors industry can be segmented into CLL (chronic lymphocytic leukaemia) and FL (follicular lymphoma). The major regional markets for phosphoinositide 3-kinase (PI3K) inhibitors are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER